Multi-layer Tablet: Current scenario and recent advances
Keywords:
Multi-layer tablet, Bi-layer tablet, Fixed Dose Combinations, Tableting technologyAbstract
The purpose of this article on tableting of multiple Active Pharmaceutical Ingredients(APIs) in the single oral solid dose in the form of Fixed Dose Combinations(FDCs), that focused on therapeutic justification, designing, its practical approach, summarize the problem encountered and parameters to be considered during development.This will help budding formulation development scientists working on generic development as such types of formulation is current need in various disease conditions.Looking to the necessity of medical practitioners,ultimately generic pharmaceutical companies taking interest in development of such formulation with correct medical justification due to various health problem not only in India but also globally. FDCs are highly popular in the Indian pharmaceutical market and also have been seen in the last few years. Presently very few generic companies are working on FDCs in the form of multilayer tablets resulting into small numbers of formulation in the market yearly.
References
. Rathod RT, Misra D. FDC of
montelukast with levocetirizine:
focus on bilayer technology. J Indian
Med Assoc. 2009; 107; 562-574.
. Chien YW. Fundamentals of
controlled-release of drug
administration: Swarbrick J. Novel
Drug Delivery System. Marcel
Dekker, New York, 1982,p. 465ă
. http://www.who.int/gho/publications/w
orld_health_statistics/en/AbdulS,Po
ddarSS. A flexible technology for
modified release of drugs: multi
layered tablets. J Control Rel.
;97; 393ă405.
. Niazi SK. Handbook of
Pharmaceutical manufacturing
formulations compressed solid
products. Informa Health care. New
York, 2004, p. 1-10.
. http://cdsco.nic.in/FDC%20Guideline
s%20_%20Revised1.pdf
. http://dsi.com/c/document_library/get
_file?uuid=eb3aac3a-96c2-4e63-
b1-
de82409b856f&groupId=12065
. http://www.who.int/medicines/areas/q
uality_safety/quality_assurance/Revi
ew-findingsPaediatricMedicnesAdmin_QAS11-
Rev1_22082011.pdf
. Shaikh RP ,Pillay V, Choonara YE,
Toit LC, Ndeseudo VMK, Bawa P,
Cooppan S. A review on multiresponsive membranous systems
for rate-modulated drug delivery.
AAPS PharSciTech2010;11; 441-
. Park JS, Shim JY, Park JS, Choi YW,
Jeong SH. A novel three-layered
tablet for extended release with
various layer formulations and in
vitro release profiles. Drug Dev Ind
Pharm.2011; 37; 664-672.
. US Patent 20120231045
. .Aboelwafa AA, Basalious EB.
Optimization and In
vivo pharmacokinetic study of a
novel controlled release venlafaxine
hydrochloride Three-Layer Tablet.
AAPS PharmSciTech.2010; 11;
ă1037.
. Park JS, Shim JY, Park JS, Choi
YW, Jeong SH.A novel threelayered tablet for extended release
with various layer formulations and
in vitro release profiles. Drug Dev
Ind Pharm.2011;37; 664ă672.
. US Patent 20040253311A1
. Patent WO/2012/090218
. Vimovo™: (naproxen/esomeprazole
magnesium) delayed-release
tablets. P T. 2010 35(9 Section 2):
ă4.
. Krishnaiah YSR, Karthikeyan RS,
Gouri Sankar V, Satyanarayana V.
Three-layer guar gum matrix
tablet formulations for oral
controlled delivery of highly soluble
trimetazidinedihydrochloride. J
Control Rel.2002;81; 45ă56.
. QR, Choi YW, Cui JH, Lee BJ.
Formulation, release characteristics
and bioavailability of novel
monolithic
hydroxypropylmethylcellulose matrix
tablet containing acetaminophen. J
Control Rel. 2005; 108; 351ă361.
. Efentakis M, Peponaki C.
Formulation study and evaluation of
matrix and three-layer tablet
sustained drug delivery systems
based on carbopols with
isosorbitemononitrate. AAPS
PharmSciTech. 2008; 9(3): 917ă
. Patent EP0922464
. http://cdsco.nic.in/FDC%20Guidelin
es%20_%20Revised1.pdf
. Behrens, Calvin, Kirsch. Multilayer
Tablets: Key Challenges and trends.
Pharm Technol. 2012; 36(3): 22-33.
. WIPO Patent WO2010137855
. USPatent 7014867
. Gautam CS, Saha L. Fixed dose
drug combinations (FDCs): rational
or irrational: a view point.Br J
ClinPharmacol.2008; 65: 795ă796.
. World Health Organisation. The use
of essential drugs, WHO technical
report series. Geneva, Switzerland;
p. 867.
. Pourkavoos. N. Unique risks,
benefits, and challenges of
developing drug-drug combination
products in a pharmaceutical
industrial setting. Combination
products in therapy, drugs, devices,
and biologics in
combination© SpringerHealthcare 2
Kottala N,Abebe A,SprockelO,B
ergumJ, Nikfar F, CuitiñoA.M.Evalua
tion of the performance
characteristics of bilayer tablets:
Part I. impact of material properties
and process parameters on the
strength of bilayer tablets. AAPS
PharmSciTech. 2012; 14: 1-7.
. WIPO Patent WO2007132281A1
. http://www.skyepharma.com/Techno
logy/Oral_Technology/Geomatrix
. http://www.accubreakpharmaceutica
ls.com/
. US Patent 4874388
. Elan drug technologies. Spheroidal
drug absorption system
(SODAS®) 2010. [(Accessed on 26
August 2010)]. Available
online: http://www.elandrugtechnolo
gies.com/oral_controlled_release/so
das.
. Gohel MC, Parikh RK, Nagori SA,
Jethwa BA. Fabrication and
evaluation of bilayer tablet
containing conventional paracetamol
and modified release diclofenac
sodium. Ind J Pharm Sci.2010;72:
-196.
. Ramesh DS, Guruvaiah HA.
Formulation and evaluation of
bilayer sustained release matrix
tablets of metformin Hcl and
pioglitazone. Amer-Euras J Sci
Res.2010; 5:176-182.
. Naeem MA, Mahmood A, Khan SA,
Shahiq Z. Development and
evaluation of controlled release
bilayer tablets containing
microencapsulated tramadol and
acetaminophen. Trop J
PharmRes.2010; 9: 347-354.
. Nagaraju R, Kaza R. Formulation
and evaluation of bilayer sustained
release tablet of salbutamol and
theophylline. Int J Pharm
Sci.Nanotechno.2009;2: 638-646.
. Atram SC, Udavant YK, Salunke RJ,
Neb GB, Shahi SR, Gulecha BS,
Padalkar AN. Formulation and
evaluation of bilayer tablet
containing metoprolol succinate and
amlodipine besylate as a model
drug for anti-hypertensive therapy. J
Pharm Res.2009;2: 1335-1347.
. Nirmal J, Sasivam S, Peddanna C,
Muralidharan S, Kumar SG,
Nagarajan M. Formulation and
evaluation of bilayer tablets of
atorvastatin calcium and nicotinic
acid. Chem Pharm Bull 2008; 56:
-1458.
. Shiyani B, Gattani S, Surana S.
Formulation and evaluation of
bilayer tablet of metoclopramide
hydrochloride and ibuprofen. AAPS
Pharm Sci Tech.2008;9: 818-827.
. http://www.drugs.com/international/a
lprax-plus.html
. http://www.drugsupdate.com/brand/
generic/Glimepiride%20+%20Metfor
min/5313
